A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy

Bone Marrow Transplantation

Volumn 26, Issue 7, 2000, Pages 763-767

  Avery, R K ^a   Adal, K A ^a   Longworth, D L ^a   Bolwell, B J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Allogeneic BMT; CMV; Pre emptive; Prophylaxis

Indexed keywords

GANCICLOVIR; PRION PROTEIN; VALACICLOVIR; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA DETERMINATION; DNA HYBRIDIZATION; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNOASSAY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MONITORING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; QUESTIONNAIRE; RISK ASSESSMENT; TISSUE CULTURE; UNITED STATES; VIRUS CULTURE;

EID: 0033754276     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702608     Document Type: Article

References (48)

1. Risk factors for cytomegalovirus infection after human marrow transplantation
2. Prophylaxis of cytomegalovirus infection after bone marrow transplantation
3. Cytomegaloviral virus infection in bone marrow transplantation recipients: Strategies for prevention and treatment
4. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand?
5. Strategies for the prevention of cytomegalovirus disease after marrow transplantation
6. The challenge of cytomegalovirus infection after bone marrow transplantation: Epidemiology, prophylaxis, and therapy
7. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation
8. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplantation
9. Prevention of cytomegalovirus infection after allogeneic bone marrow transplantation
10. Cytomegalovirus pneumonia: Presentation, diagnosis, and treatment
11. Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts
12. Cytomegalovirus and marrow function
13. Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-v-host disease
14. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
15. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
16. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
17. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European bone marrow transplant group
18. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients
19. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic bone marrow transplantation
20. The impact of long-term acyclovir on cytomegalovirus infection and survival in allogeneic bone marrow transplantation
21. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
22. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients
23. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
24. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
25. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
26. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
27. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation
28. Use of preemptive ganciclovir based solely on asymptomatic pulmonary cytomegalovirus infection in marrow transplant recipients - Long-term follow-up
29. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
30. CMV-antigenemia after allogeneic bone marrow transplantation: Correlation of CMV-antigen positive cell numbers with transplant-related mortality
31. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation - A randomized double-blind study
32. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: Examination of a preemptive plan of ganciclovir therapy
33. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
34. Monitoring of CMV infection: A comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation
35. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis
36. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
37. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: Absence of clinical cytomegalovirus infection
38. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients
39. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T-cell depleted marrow transplant
40. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants
41. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors
42. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
43. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation
44. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
45. Practices for cytomegalovirus diagnosis, prophylaxis, and treatment in allogeneic bone marrow transplant recipients; a report from the working party for infectious diseases of the EBMT
46. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
47. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients
48. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis